Code of Federal Regulations: Containing a Codification of Documents of General Applicability and Future Effect as of December 31, 1948, with Ancillaries and IndexDivision of the Federal Register, the National Archives, 1998 Special edition of the Federal Register, containing a codification of documents of general applicability and future effect ... with ancillaries. |
No grāmatas satura
6.–10. rezultāts no 99.
368. lappuse
... concentrations to prepare the standard response line solutions . The reference concentration of the assay is the mid concentration of the response line . Amoxicillin Antibiotic Drying condi- tions ( method number as list-. 368 § 436.105 ...
... concentrations to prepare the standard response line solutions . The reference concentration of the assay is the mid concentration of the response line . Amoxicillin Antibiotic Drying condi- tions ( method number as list-. 368 § 436.105 ...
372. lappuse
... concentration solu- tion and the other three cylinders with the concentration of the response line under test . Thus , there will be 36 ref- erence concentration zones of inhibi- tion and nine zones of inhibition for each of the four ...
... concentration solu- tion and the other three cylinders with the concentration of the response line under test . Thus , there will be 36 ref- erence concentration zones of inhibi- tion and nine zones of inhibition for each of the four ...
373. lappuse
... concentrations for the standard response line solutions by fur- ther diluting an aliquot of the working standard stock solution . The reference concentration of the assay is the mid concentration of the standard response line . ( b ) ...
... concentrations for the standard response line solutions by fur- ther diluting an aliquot of the working standard stock solution . The reference concentration of the assay is the mid concentration of the standard response line . ( b ) ...
375. lappuse
... concentration of the standard response line ( prepare as described in paragraph ( a ) of this section ) and of the sample solution in each set of three replicate tubes ( as described in §436.100 ( b ) ( 1 ) ) . Fifteen tubes are used ...
... concentration of the standard response line ( prepare as described in paragraph ( a ) of this section ) and of the sample solution in each set of three replicate tubes ( as described in §436.100 ( b ) ( 1 ) ) . Fifteen tubes are used ...
380. lappuse
... concentration as listed for each antibiotic . Dissolve an accu- rately weighed aliquot ( approximately 30 to 60 milligrams ) of the sample , dilute to the appropriate final concentration , and proceed as directed in paragraphs ( c ) and ...
... concentration as listed for each antibiotic . Dissolve an accu- rately weighed aliquot ( approximately 30 to 60 milligrams ) of the sample , dilute to the appropriate final concentration , and proceed as directed in paragraphs ( c ) and ...
Saturs
279 | |
285 | |
290 | |
299 | |
310 | |
331 | |
339 | |
340 | |
223 | |
236 | |
238 | |
239 | |
240 | |
256 | |
257 | |
262 | |
263 | |
265 | |
270 | |
275 | |
351 | |
483 | |
588 | |
593 | |
696 | |
699 | |
761 | |
826 | |
865 | |
890 | |
911 | |
949 | |
Citi izdevumi - Skatīt visu
Bieži izmantoti vārdi un frāzes
abbre abbreviated application abbreviated new drug acid active ingredient adverse drug experience agency amended antibiotic application or abbreviated bacitracin bioavailability bioequivalence cation Center for Drug certification chapter clinical hold clinical investigation conducted control number copy Cosmetic Act digoxin dosage form dose Drug Administration drug application Drug Evaluation drug prod drug product Drug products containing drug substance Evaluation and Research Federal Food Food and Drug graph gredients hearing hydrochloride identified information requirements ap insulin intended inves investigational new drug labeling manufacturer marketing meet ment milligrams milliliters misbranded neomycin notice oral dosage orphan drug OTC drug product package paragraph percent person plication polymyxin proposed protocol recognized as safe reference listed drug request safe and effective safety section 502 Sodium sponsor statement submission Subpart sulfate tained tigational tion tive treatment treatment IND vestigational viated warning